These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 24443894)

  • 21. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
    Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
    PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.
    ElNahass YH; Badawy RH; ElRefaey FA; Nooh HA; Ibrahiem D; Nader HA; Mahmoud HK; ElMetnawy WH
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):721-725. PubMed ID: 32212799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation.
    Raveendran S; Sarojam S; Vijay S; Geetha AC; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):4095-101. PubMed ID: 25987093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
    Mason EF; Kuo FC; Hasserjian RP; Seegmiller AC; Pozdnyakova O
    Am J Hematol; 2018 Aug; 93(4):504-510. PubMed ID: 29274134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
    Zhou KG; Jiang LJ; Shang Z; Wang J; Huang L; Zhou JF
    Leuk Lymphoma; 2012 Dec; 53(12):2423-9. PubMed ID: 22616558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Isocitrate dehydrogenase gene mutations in acute myeloid leukemia].
    Zhou XJ; Zhang SJ; Qiao C; Shen YF; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):902-6. PubMed ID: 21867611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
    Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
    Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
    Green CL; Evans CM; Zhao L; Hills RK; Burnett AK; Linch DC; Gale RE
    Blood; 2011 Jul; 118(2):409-12. PubMed ID: 21596855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Mi RH; Lu XD; Wei XD; Fan RH; Yin QS; Hu JY; Wang Q; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):610-3. PubMed ID: 22338155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
    Zarnegar-Lumley S; Alonzo TA; Gerbing RB; Othus M; Sun Z; Ries RE; Wang J; Leonti A; Kutny MA; Ostronoff F; Radich JP; Appelbaum FR; Pogosova-Agadjanyan EL; O'Dwyer K; Tallman MS; Litzow M; Atallah E; Cooper TM; Aplenc RA; Abdel-Wahab O; Gamis AS; Luger S; Erba H; Levine R; Kolb EA; Stirewalt DL; Meshinchi S; Tarlock K
    Blood Adv; 2023 Oct; 7(19):5941-5953. PubMed ID: 37267439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia.
    Kuzmanovic M; Tosic N; Colovic N; Karan-Djurasevic T; Spasovski V; Radmilovic M; Nikcevic G; Suvajdzic-Vukovic N; Tomin D; Vidovic A; Virijevic M; Pavlovic S; Colovic M
    Acta Haematol; 2012; 128(4):203-12. PubMed ID: 22906848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
    Middeke JM; Metzeler KH; Röllig C; Krämer M; Eckardt JN; Stasik S; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Brümmendorf TH; Naumann R; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Görlich D; Sauerland C; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Kaufmann M; Kunadt D; Wörmann B; Sockel K; von Bonin M; Herold T; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Baldus CD; Ehninger G; Schetelig J; Hiddemann W; Bornhäuser M; Stölzel F; Thiede C
    Blood Adv; 2022 Mar; 6(5):1394-1405. PubMed ID: 34794176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
    Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
    J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
    Luo LQ; Peng ZY; Liu X; Yu WZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
    Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A
    Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
    Ravandi F; Patel K; Luthra R; Faderl S; Konopleva M; Kadia T; Brandt M; Pierce S; Kornblau S; Andreeff M; Wang X; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2012 May; 118(10):2665-73. PubMed ID: 22020636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.